Merck KGaA (OTCMKTS:MKKGY) Downgraded by Zacks Research to Strong Sell

Zacks Research downgraded shares of Merck KGaA (OTCMKTS:MKKGY) from a hold rating to a strong sell rating in a report published on Monday,Zacks reports.

Several other brokerages have also recently commented on MKKGY. UBS Group cut Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. HSBC raised Merck KGaA to a “hold” rating in a research note on Monday, July 6th. Five investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Merck KGaA Stock Performance

MKKGY opened at $30.89 on Monday. Merck KGaA has a fifty-two week low of $23.73 and a fifty-two week high of $34.19. The firm has a market cap of $19.96 billion, a PE ratio of 15.92, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.09, a current ratio of 1.69 and a debt-to-equity ratio of 0.37. The business has a fifty day simple moving average of $31.51 and a 200-day simple moving average of $30.23.

Merck KGaA Company Profile

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest pharmaceutical and chemical businesses. The company operates independently from Merck & Co, Inc, the U.S.-based company that uses the Merck name in the United States and Canada.

Merck KGaA operates through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, analytical technologies and bioprocessing solutions used by pharmaceutical and biotechnology companies, academic institutions and industrial laboratories.